Capricor Therapeutics, Inc. (NASDAQ: CAPR)is focused on discovering, developing and marketing first-in-class therapeutics for the treatment of diseases. Presently, the company is positioned at the forefront of one of the largest segments of the U.S. healthcare industry:  heart disease. Capricor’s … Continue reading →

Capnia, Inc. (NASDAQ: CAPN) develops diagnostic and therapeutic products based on its proprietary technology for the precision metering of gas flow. Operating primarily in the U.S., the company offers CoSense for the diagnosis of excessive hemolysis in neonates, a condition … Continue reading →

Can-FiteBioPharma Ltd. (NYSE: CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase II and III clinical development stage, which address autoimmune-inflammatory and cancer … Continue reading →

Founded more than 25 years ago, Cadiz Inc. (NASDAQ: CDZI) is a Los Angeles-based renewable resource company dedicated to pursuing sustainable projects through the responsible stewardship of its land and water resources. The company owns more than 70 square miles … Continue reading →

Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI)is developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases, e.g. Amyotrophic Lateral Sclerosis (ALS a.k.a. Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD). NurOwn is the company’s own, first-of-its-kind technology … Continue reading →

BioTime, Inc. (NYSE: BTX) is building a dominant company in the field of regenerative medicine. The company’s strategy is to be the leader in the development of pluripotent stem cell-based technologies and to apply those new technologies in the treatment … Continue reading →

Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) is focused on discovering and developing direct-acting antivirals to treat infections that affect a significant number of patients globally. The company has four product candidates with limited therapeutic options in development. Biota is currently enrolling … Continue reading →

BioSpecifics Technologies Corp. (NASDAQ: BSTC) is a profitable, commercial-stage biopharmaceutical company that has developed injectable collagenase for 12 clinical indications to date. Injectable collagenase is approved for marketing as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and abroad … Continue reading →

Through its patented platform technologies, BioPharmX Corporation (NYSE MKT: BPMX) develops unique health and wellness products for licensing and commercialization in pharmaceutical, over-the-counter and supplemental use. The BioPharmX team aims to touch lives by providing relief and restoring well-being so … Continue reading →

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), an innovative biopharmaceutical company, is developing a universal flu vaccine designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. BiondVax’s go-to-market strategy for its … Continue reading →